PI-88 in Hepatocellular Carcinoma After Hepatectomy

Carcinoma, Hepatocellular Clinical Trial

Official title:

A Randomized, Multi-centre, Efficacy Evaluation of PI-88 in Patients With Hepatocellular Carcinoma After Hepatectomy - A Phase II Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00247728
• Other study ID #: MG 002
• Secondary ID: PR88204
• Status: Completed
• Phase: Phase 2
• Start date: June 2004
• Est. completion date: June 2008

Study information

• Verified date: June 2022
• Source: Cellxpert Biotechnology Corp.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of PI-88 to inhibit or reduce tumor recurrence in patients with hepatocellular carcinoma following hepatectomy.

Description:

Although early diagnosis and treatment improve survival, hepatocellular carcinoma (HCC) is rarely cured and recurs frequently after regional therapy or transplantation. Hepatic resection can improve 5-year recurrence-free survival by up to 25%. Micrometastases of HCC have been detected by molecular techniques in 88% of patients at the time of surgery, and probably cause postoperative recurrence. Efforts to reduce the risk of recurrence after a curative resection have been tried, including various regimens of adjuvant and neoadjuvant therapy.

In this study , an anti-angiogenic agent, PI-88, is being used as an adjuvant therapy for HCC patients after curative hepatic resection. The efficacy endpoints, including tumour non-recurrence rate, time to first recurrence and 1-year survival rate are being evaluated. Several risk factors associated with tumour recurrence are also being analysed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 172
• Est. completion date: June 2008
• Est. primary completion date: June 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients have voluntarily given written informed consent

• Age = 18 years but = 75 years

• Males or females

• Histological diagnosis of hepatocellular carcinoma

• Curative hepatectomy within the past 4-6 weeks

• ECOG performance status of 0 to 2

• Cardiac functional capacity = to class II (New York Heart Association)

• Patients with adequate renal, hepatic, and haematopoietic function as defined by:

• Serum creatinine = 2.0 mg/dL

• Total bilirubin < 2.5 mg/dL

• Neutrophil count > 1.5 x 10^9/L

• ALT < 5 x upper limit of normal (ULN)

• White blood cell (WBC) count = 3 x 10^9/L

• Platelet count = 80 x 10^9/L

• Prothrombin time international normalized ratio (PT-INR) = 1.3 (or PT-INR = 1.4 but PT within normal range)

• Activated partial thromboplastin time (APTT) < ULN

Exclusion Criteria:

• Patients with history of allergy and/or hypersensitivity to anticoagulants/thrombolytic agents, especially heparin.

• Patients with history of immune mediated thrombocytopenia, thrombotic thrombocytopenic purpura, or other platelet disease

• Patients with previous positive result in a heparin-induced thrombocytopenia (HIT) antibody test.

• Patients with any tumour metastasis.

• Patients with uncontrolled infection or serious infection within the past 4 weeks.

• Patients with myocardial infarction, stroke, or congestive heart failure within the past 3 months.

• Patients with history of inflammatory bowel disease, any other abnormal bleeding tendency, or patients at risk of bleeding due to open wounds or planned surgery.

• Patients with acute or chronic gastrointestinal bleeding within the past 1 year.

• Patients with a history of drug abuse or psychiatric disorder.

• Patients with known HIV infection or AIDS-related illness.

• Patients who received other investigational or anti-neoplastic medication within the past 4 weeks.

• Use of aspirin, aspirin-containing medications, non-steroidal anti-inflammatory drugs (except for COX-2 inhibitors), heparin, low molecular weight heparin, warfarin, anti-platelet drugs, or any other anticoagulant medications 2 weeks prior to or during the study period.

• Women who are pregnant or breast-feeding.

• Women of child-bearing potential who are not using an adequate method of contraception.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular

Intervention

Drug:
• PI-88
Once-daily SC injection for four consecutive days per week, for 3 weeks out of every 4 weeks

Locations

Country	Name	City	State
Taiwan	Kaohsiung Veterans General Hospital	Kaohsiung
Taiwan	China Medical University Hospital	Taichung
Taiwan	Taichung Veterans General Hospital	Taichung
Taiwan	National Cheng Kung University Hospital	Tainan
Taiwan	National Taiwan University Hospital	Taipei
Taiwan	Chang Gung Memorial Hospital-Linkou Medical Centre	Taoyuan

Sponsors (2)

Lead Sponsor	Collaborator
Cellxpert Biotechnology Corp.	Medigen Biotechnology Corporation

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumour Non-recurrence Rate	The tumor non-recurrence rate at the end of the 48-week study period	Week 48
Secondary	Time to Recurrence	Time to recurrence during the 48-week study period	until confirmed tumour recurrence, or for a maximum of 48 weeks
Secondary	Survival Rate	Survival rate at the end of the 48-week study period	Week 48